140 related articles for article (PubMed ID: 9155645)
1. Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone.
Delehanty LL; Payne JA; Farrow SN; Brown R; Champion BR
Immunology; 1997 Mar; 90(3):383-7. PubMed ID: 9155645
[TBL] [Abstract][Full Text] [Related]
2. Fas gene mutation in the progression of adult T cell leukemia.
Maeda T; Yamada Y; Moriuchi R; Sugahara K; Tsuruda K; Joh T; Atogami S; Tsukasaki K; Tomonaga M; Kamihira S
J Exp Med; 1999 Apr; 189(7):1063-71. PubMed ID: 10190897
[TBL] [Abstract][Full Text] [Related]
3. Selection for drug resistance results in resistance to Fas-mediated apoptosis.
Landowski TH; Gleason-Guzman MC; Dalton WS
Blood; 1997 Mar; 89(6):1854-61. PubMed ID: 9058704
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis.
Walker LS; McLeod JD; Boulougouris G; Patel YI; Hall ND; Sansom DM
Immunology; 1998 May; 94(1):41-7. PubMed ID: 9708185
[TBL] [Abstract][Full Text] [Related]
5. Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells.
Chiba T; Takahashi S; Sato N; Ishii S; Kikuchi K
Eur J Immunol; 1996 May; 26(5):1164-9. PubMed ID: 8647182
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP.
Bénéteau M; Daburon S; Moreau JF; Taupin JL; Legembre P
Cancer Res; 2007 Jan; 67(1):108-15. PubMed ID: 17210689
[TBL] [Abstract][Full Text] [Related]
7. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.
Schattner EJ; Elkon KB; Yoo DH; Tumang J; Krammer PH; Crow MK; Friedman SM
J Exp Med; 1995 Nov; 182(5):1557-65. PubMed ID: 7595225
[TBL] [Abstract][Full Text] [Related]
8. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.
Cruz AC; Ramaswamy M; Ouyang C; Klebanoff CA; Sengupta P; Yamamoto TN; Meylan F; Thomas SK; Richoz N; Eil R; Price S; Casellas R; Rao VK; Lippincott-Schwartz J; Restifo NP; Siegel RM
Nat Commun; 2016 Dec; 7():13895. PubMed ID: 28008916
[TBL] [Abstract][Full Text] [Related]
9. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb.
Fadeel B; Thorpe J; Chiodi F
Int Immunol; 1995 Dec; 7(12):1967-75. PubMed ID: 8746566
[TBL] [Abstract][Full Text] [Related]
10. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
11. The conformational alteration of the mutated extracellular domain of Fas in an adult T cell leukemia cell line.
Maeda T; Nakayama S; Yamada Y; Sugahara K; Isomoto H; Tawara M; Yamasaki R; Onimaru Y; Matsushita T; Ohzono Y; Kamihira S
Biochem Biophys Res Commun; 2002 Sep; 296(5):1251-6. PubMed ID: 12207908
[TBL] [Abstract][Full Text] [Related]
12. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines.
Peter ME; Dhein J; Ehret A; Hellbardt S; Walczak H; Moldenhauer G; Krammer PH
Int Immunol; 1995 Nov; 7(11):1873-7. PubMed ID: 8580085
[TBL] [Abstract][Full Text] [Related]
13. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of an eight amino acid domain shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and antigenic analysis.
Silvestris F; Cocco T; Cafforio P; Calvani N; Dammacco F
Mol Med; 2000 Jun; 6(6):494-508. PubMed ID: 10972086
[TBL] [Abstract][Full Text] [Related]
15. Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.
Debatin KM; Beltinger C; Böhler T; Fellenberg J; Friesen C; Fulda S; Herr I; Los M; Scheuerpflug C; Sieverts H; Stahnke K
Biochem Soc Trans; 1997 May; 25(2):405-10. PubMed ID: 9191126
[No Abstract] [Full Text] [Related]
16. Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing.
Munker R; Marini F; Jiang S; Savary C; Owen-Schaub L; Andreeff M
Hematol Cell Ther; 1997 Apr; 39(2):75-8. PubMed ID: 9168303
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Fas-mediated apoptosis in human hepatoma cells.
Natoli G; Ianni A; Costanzo A; De Petrillo G; Ilari I; Chirillo P; Balsano C; Levrero M
Oncogene; 1995 Sep; 11(6):1157-64. PubMed ID: 7566976
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)-mediated apoptosis in activation-induced T cell death involves calcineurin and protein kinase C, respectively.
Tóth R; Szegezdi E; Molnár G; Lord JM; Fésüs L; Szondy Z
Eur J Immunol; 1999 Feb; 29(2):383-93. PubMed ID: 10064053
[TBL] [Abstract][Full Text] [Related]
19. IL-7 sensitizes human pre-B cells but not pro-B cells to Fas/APO-1 (CD95)-mediated apoptosis.
Levy Y; Benlagha K; Buzyn A; Colombel M; Brouet JC; Lassoued K
Clin Exp Immunol; 1997 Nov; 110(2):329-35. PubMed ID: 9367421
[TBL] [Abstract][Full Text] [Related]
20. Modulation of fas-mediated apoptosis in osteosarcoma cell lines.
Hamada T; Komiya S; Yano H; Zenmyo M; Hiraoka K; Inoue A; Morimatsu M
Int J Oncol; 1999 Dec; 15(6):1125-31. PubMed ID: 10568818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
